Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《International Eye Science》 2019-04
Add to Favorite Get Latest Update

Medication and progression of diabetic macular edema

De-Shuang Li;Liang Zhang;Bo Qin;Guizhou Medical University;The Affiliated Shenzhen Eye Hospital of Jinan University,Joint College of Optometry of Shenzhen University, Shenzhen Key Laboratory of Ophthalmology, Ocular Trauma Treatment and Stem Cell Differentiation Public Service Platform of Shenzhen;  
Diabetic macular edema(DME) is one of the common eye complications in diabetic patients, and is also the main cause of visual impairment in diabetic patients. Vascular endothelial growth factor(VEGF) is currently an important target for DME therapy, the latest DME guidelines point out that anti-VEGF can be used as a first-line treatment for all types of DME. Anti-VEGF and glucocorticoid are widely used medications in DME treatment at present. Besides, numbers of newtherapies which include anti-VEGF DARPin(designed ankyrin repeat proteins, DARPins), vascular adhesion protein, integrin antagonists and others, are in development. This article reviews the medication and emerging treatment of diabetic macular edema.
【Fund】: 深圳市卫生计生系统科研项目(No.SZLY2017027)~~
【CateGory Index】: R587.2;R774.5
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved